Akesys Medical and Elixir Medical Corporation said today that it implanted its 1st Prava sirolimus eluting bioresorbable peripheral scaffold for the treatment of blockages in the superficial femoral artery.
The scaffold was developed to keep the large artery in the thigh open and restore blood flow to the leg and resorb into the body, making us of the bioresorbable tech licensed to Akesys by Elixir.
Akesys touted its stent as extending drug release over 6 months and sustaining initial clinical outcomes over the long term compared to shorter duration drug-eluting balloons.
Get the full story at our sister site, Drug Delivery Business News.
The post Akesys, Elixir Medical tout 1st implant for Prava bioresorbable peripheral stent appeared first on MassDevice.